Tamoxifen (BioCAD00000018196)
{$topic}
Metabolite Card
Formula: C26H29NO (371.2249)
SMILES: CC\C(=C(/C1=CC=CC=C1)C1=CC=C(OCCN(C)C)C=C1)C1=CC=CC=C1
Synonyms [en]
tamoxifen; Tamoxifene; (Z)-2-(4-(1,2-Diphenyl-1-butenyl)phenoxy)-N,N-dimethylethanamine; Crisafeno; trans-Tamoxifen; Tamoxifeno
Last reviewed on 2024-06-28.
Cite this Page
Tamoxifen. 数据之源,洞见之始. SMRUCC genomics institute, a synthetic life researcher from China.
https://biocad_registry.innovation.ac.cn/s/(-)-arctiin
(retrieved
2026-01-03) (CAD Registry RN: BioCAD00000018196). Licensed
under the Attribution-Noncommercial 4.0 International License (CC BY-NC 4.0).
Note
Tamoxifen is only found in individuals that have used or taken this drug. It is one of the selective estrogen receptor modulators with tissue-specific activities. Tamoxifen acts as an anti-estrogen (inhibiting agent) in the mammary tissue, but as an estrogen (stimulating agent) in cholesterol metabolism, bone density, and cell proliferation in the endometrium. [PubChem]Tamoxifen binds to estrogen receptors (ER), inducing a conformational change in the receptor. This results in a blockage or change in the expression of estrogen dependent genes. The prolonged binding of tamoxifen to the nuclear chromatin of these results in reduced DNA polymerase activity, impaired thymidine utilization, blockade of estradiol uptake, and decreased estrogen response. It is likely that tamoxifen interacts with other coactivators or corepressors in the tissue and binds with different estrogen receptors, ER-alpha or ER-beta, producing both estrogenic and antiestrogenic effects.
DBLinks
- CAS Registry Number: 10540-29-1
- PubChem CID: 2733526
- ChEBI: 41774
- HMDB: HMDB0014813
- LipidMaps:
- KEGG: C07108
- BioCyc:
- NCBI MeSH: Tamoxifen
- Wikipedia: Tamoxifen
Other DBLinks
- CAS Registry Number: 10540-29-1
- PubChem: 2733526
- ChEBI: ChEBI:41774
- HMDB: HMDB0014813
- KEGG: C07108
- KEGG: D08559
- NCBI MeSH: Tamoxifen
- Wikipedia: Tamoxifen
- DrugBank: DB00675
- RefMet: RM0187646
- MoNA: AU271501
- MoNA: AU271502
- MoNA: AU271503
- MoNA: AU271504
- MoNA: AU271505
- MoNA: AU271506
- MoNA: CCMSLIB00000077066
- MoNA: LU107301
- MoNA: LU107302
- MoNA: LU107303
- MoNA: LU107304
- MoNA: LU107305
- MoNA: LU107306
- MoNA: MoNA033368
- MoNA: MoNA033370
- MoNA: MoNA033371
- MoNA: MoNA037615
- MoNA: SM861203
- Metlin: METLIN_593
Class / Ontology
- WishartLab ClassyFire: [Stilbenes] Stilbenes
- RefMet: [Stilbenes] Stilbenes
- ChEBI: [CHEBI:41774] tamoxifen
| ID | EC Number | Name |
|---|---|---|
| KEGG:R08266 | 1.14.13.8 | tamoxifen,NADPH:oxygen oxidoreductase (N-oxide-forming) |
| KEGG:R08267 | 1.14.14.1 | C07108 + C00005 + C00007 + C00080<=>C05011 + C00006 + C00001 |
| KEGG:R08268 | 1.14.14.- | C07108<=>C16546 |
| KEGG:R08271 | 1.14.14.- | C07108 + C00005 + C00007 + C00080<=>C16544 + C00006 + C00001 |
Taxonomy Source
Pathway Synthetic
| pathway id | name |
|---|---|
| Reactome:R-BTA-1430728 | Metabolism |
| Reactome:R-BTA-211945 | Phase I - Functionalization of compounds |
| Reactome:R-CEL-211859 | Biological oxidations |
| Reactome:R-CFA-1430728 | Metabolism |
| Reactome:R-HSA-211859 | Biological oxidations |
| Reactome:R-HSA-217271 | FMO oxidises nucleophiles |
| Reactome:R-MMU-1430728 | Metabolism |
| Reactome:R-MMU-211859 | Biological oxidations |
| Reactome:R-MMU-217271 | FMO oxidises nucleophiles |
| Reactome:R-RNO-211945 | Phase I - Functionalization of compounds |
| Reactome:R-SSC-211945 | Phase I - Functionalization of compounds |
| Reactome:R-BTA-211859 | Biological oxidations |
| Reactome:R-BTA-217271 | FMO oxidises nucleophiles |
| Reactome:R-CEL-217271 | FMO oxidises nucleophiles |
| Reactome:R-DRE-211945 | Phase I - Functionalization of compounds |
| Reactome:R-RNO-211859 | Biological oxidations |
| Reactome:R-RNO-217271 | FMO oxidises nucleophiles |
| Reactome:R-SSC-1430728 | Metabolism |
| Reactome:R-SSC-211859 | Biological oxidations |
| Reactome:R-SSC-217271 | FMO oxidises nucleophiles |